Evolus

We are proud to congratulate our CFO, Sandra Beaver, on receiving the Rising Star award at the 2nd annual CFO Leadership Awards, hosted by StrategicCFO360 and the The CFO Leadership Council. This distinguished honor highlights Sandra’s remarkable early career achievements, including her innovation, versatility, and strategic leadership in the finance community. Her contributions continue to propel Evolus forward, and we’re excited to celebrate this well-deserved recognition! A special thank you to Jack McCullough, President of the CFO Leadership Council, and KimMarie Hagerty, publisher of the StrategicCFO360 channel, for presenting this prestigious award.    #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics   📸Credit: Ben Hider Photography

ICYMI, Evolus CEO David Moatazedi was featured in Nasdaq’s #BehindtheBell series where he discussed our leadership position in performance beauty, cash-pay model, and innovation in #aesthetics. Check out the interview: https://lnkd.in/eCxZSyvY $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Last week, Evolus CEO David Moatazedi, CFO Sandra Beaver, and CMO Rui Avelar, MD, joined other leaders at the Stifel Healthcare Conference in New York City to discuss our flagship toxin, expectation of our line of injectable HA gels, and outlook for 2025 and beyond. Listen to a replay of the discussion here: https://lnkd.in/eYtd5rUb $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We’re excited to announce that for the second year in a row Evolus has made the Deloitte Technology Fast 500™, recognizing the fastest growing companies in North America! This achievement highlights the strength of our team, the success of our customer-focused strategy, and our commitment to innovation in performance beauty. Thank you to our customers and partners for being an integral part of this journey as we continue to redefine #aesthetics. https://lnkd.in/ev8PTq8 $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Congratulations to Jeffrey Plumer, Evolus’ General Counsel, on being named the Orange County Business Journal’s Public Company General Counsel of the Year! Jeff’s leadership and strategic guidance have been instrumental in shaping our success and navigating the landscape of the #aesthetics industry. We’re proud to have him on our team and thrilled to see his exceptional work recognized. #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We are excited to share the Nasdaq #BehindtheBell interview featuring Evolus President & CEO David Moatazedi. David dives into our focus as a performance beauty company, driven by a bold focus on cash-pay and a commitment to innovation in aesthetics.   It’s an exciting time to be part of the Evolus story as we continue our journey to redefine the #aesthetics industry and achieve new growth milestones. Thank you to Nasdaq for this opportunity and for supporting our vision! Check out the full interview: https://lnkd.in/eCxZSyvY   #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Today, we reported our Q3 2024 financials. Our management team will hold a conference call to discuss the results today at 4:30 p.m. ET.    Read the release and access the conference call link here: https://lnkd.in/eaNsW-fV $EOLS #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We’re excited to announce that we will be participating in the upcoming Stifel Financial Corp. 2024 Healthcare Conference in New York City! Join us on November 19th for a fireside chat with our management team, where we’ll dive into our unique position as the only performance beauty brand focused exclusively on cash-pay aesthetics.   Alongside the fireside chat, our team will be hosting one-on-one meetings with investors to discuss our innovation in the fast-growing #aesthetic market and our vision for setting new standards in beauty. If you’re attending the conference, we look forward to connecting with you! Fireside Chat Webcast: https://lnkd.in/eYtd5rUb   #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We’re excited to announce that Evolus has secured EU MDR certification for our line of four injectable hyaluronic acid (HA) gels, a critical milestone in our journey to expand our portfolio and reshape the global dermal filler market! This achievement doubles our addressable market in Europe to $1.8 billion and sets a new standard for performance beauty, positioning it as a premier choice for #aesthetic professionals and patients alike. We’re look forward to launching a limited experience program with top aesthetic practitioners, paving the way for a broader European launch in 2025. #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We are excited to announce that our Evolus Rewards™ patient loyalty program has surpassed 1 million enrolled consumers, achieving over 2 million redemptions! This milestone showcases our commitment to making beauty accessible through #innovative solutions. We’re also excited to launch Club Evolus™ on November 4th, the first subscription-based membership program from a neurotoxin manufacturer, offering even more value to consumers and practices alike.   #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics